CellCentric has begun a Phase Ib/IIa clinical trial of CCS1477 to treat late-stage prostate cancer after receiving regulatory approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA).
The Institute of Cancer Research in London, UK, Regius professor and The Royal Marsden NHS Foundation Trust consultant medical oncologist Johann de Bono is the chief investigator of the trial, which seeks to enrol 120 patients.
During the first-in-man trial, CCS1477’s tolerability and efficacy will be evaluated for the treatment of late-stage prostate cancer.
CCS1477 will also be tested as a monotherapy, as well as in combination with Zytiga and Xtandi at a number of sites in the UK, including Sir Bobby Robson Cancer Trials Research Centre, Newcastle and Northern Ireland Cancer Centre, Belfast.
The trial is also expected to be expended to various sites in the US, including Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia.
Bono said: “One of the largest areas of unmet need in prostate cancer is the growing number of men who become resistant to treatment with second-generation anti-hormonal drugs.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
“Targeting both the androgen receptor and its splice variants with a novel drug such as CCS1477 could prove to be a new and exciting way to treat this disease.”
CCS1477 is a potent, selective, orally bioavailable inhibitor that features conserved bromodomains of twin histone acetyl transferase proteins, p300 and CBP.
Inhibition of p300/CBP can significantly reduce the expression of the drivers of late-stage prostate cancer; the androgen receptor (AR), AR-splice variants (AR-SV) and c-Myc.
Reducing AR-SV is said to address inherent or acquired resistance to current second generation anti-androgen treatments abiraterone (Zytiga), enzalutamide (Xtandi) and apalutamide (Erleada).